Peggy J de Vos van Steenwijk
Overview
Explore the profile of Peggy J de Vos van Steenwijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van de Sande A, van Baars R, Koeneman M, Gerestein C, Kruse A, van Esch E, et al.
BJOG
. 2024 Mar;
PMID: 38556619
Objective: To investigate the efficacy of imiquimod in women with residual or recurrent cervical intraepithelial neoplasia (rrCIN), compared with large loop excision of the transformation zone (LLETZ). Design: Randomised controlled...
2.
Schuurman T, Schaafsma M, To K, Verhoef V, Sikorska K, Siebers A, et al.
Lancet Oncol
. 2023 Nov;
24(12):1349-1358.
PMID: 37952541
Background: The optimal follow-up strategy to detect recurrence after fertility-sparing surgery for early stage cervical cancer is unknown. Tailored surveillance based on individual risks could contribute to improved efficiency and,...
3.
Abdulrahman Z, Hendriks N, Kruse A, Somarakis A, van de Sande A, van Beekhuizen H, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36323430
Background: The complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod....
4.
Speetjens F, Welters M, Slingerland M, van Poelgeest M, de Vos van Steenwijk P, Roozen I, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36261215
Background: Amplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen...
5.
Muntinga C, de Vos van Steenwijk P, Bekkers R, van Esch E
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268523
Cervical high-grade squamous intraepithelial lesions (cHSILs) develop as a result of a persistent high-risk human papilloma virus (hrHPV) infection. The natural course of cHSIL is hard to predict, depending on...
6.
Hendriks N, Koeneman M, van de Sande A, Penders C, Piek J, Kooreman L, et al.
J Immunother
. 2022 Feb;
45(3):180-186.
PMID: 35180719
Topical imiquimod could be an alternative, noninvasive, treatment modality for high-grade cervical intraepithelial neoplasia (CIN). However, evidence is limited, and there are no studies that compared treatment effectiveness and side...
7.
Schreurs M, de Vos van Steenwijk P, Romano A, Dieleman S, Werner H
J Clin Med
. 2021 Jul;
10(13).
PMID: 34209916
: Interest is growing in the dynamic role of gut microbiome disturbances in human health and disease. No direct evidence is yet available to link gut microbiome dysbiosis to endometrial...
8.
Kortekaas K, Bastiaannet E, van Doorn H, de Vos van Steenwijk P, Ewing-Graham P, Creutzberg C, et al.
Gynecol Oncol
. 2020 Sep;
159(3):649-656.
PMID: 32972785
Objective: There is great need for better risk stratification in vulvar squamous cell carcinoma (VSCC). Our aim was to define the prognostic significance of stratifying VSCC based on p16 and...
9.
Abdulrahman Z, de Miranda N, Hellebrekers B, de Vos van Steenwijk P, van Esch E, van der Burg S, et al.
Int J Cancer
. 2020 Jun;
147(10):2914-2923.
PMID: 32574376
Immunotherapy of vulvar high-grade squamous intraepithelial lesion (vHSIL) is investigated as an alternative for surgery, because of high comorbidity and risk of recurrence. Limited evidence exists on the role and...
10.
Abdulrahman Z, de Miranda N, van Esch E, de Vos van Steenwijk P, Nijman H, Welters M, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32169871
Background: Vulvar high-grade squamous intraepithelial lesion (vHSIL) is predominantly induced by high-risk human papilloma virus type 16 (HPV16). In two independent trials, therapeutic vaccination against the HPV16 E6 and E7...